Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

BrainStorm posts $1.7M Q3 net loss as NurOwn Phase 3b ALS trial awaits start

The cell therapy developer reports minimal cash of about $0.35M while still preparing its ENDURANCE study in earlier-stage ALS under an FDA-agreed Special Protocol Assessment.

16 Nov 2026 · Brainstorm Cell Therapeutics Inc. BCLI · Company news

BrainStorm Cell Therapeutics reported results for the quarter ended 30 September 2026 on 16 November, disclosing a net loss of about $1.7M. Cash and restricted cash totalled roughly $0.35M at the end of the period.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Brainstorm Cell Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →